Oncodesign® presents its latest scientific advances at the AACR annual conference

Eight posters from novel cancer therapy company include special focus on its chi-Mice® humanized chimeric models, at American Association for Cancer Research annual conference in Washington DC from April 17-21

Oncodesign will be on booth 1747

Dijon (France), April 12, 2010 – Oncodesign, a specialist in the identification of novel cancer therapies, announces today that it will present eight scientific posters at the annual conference of the American Association for Cancer Research in Washington DC, April 17-20.

As in previous years, Oncodesign is showcasing its latest technological advances at the AACR. The company’s translational research platform is focused on two main technology areas: the development of new experimental models and new pharmaco-imaging tools. In the field of preclinical models, Oncodesign is presenting its new platform for the production of “chi-Mice®”, humanized chimeric animals. “These models combine our research into grafting tumors directly from patients and the reconstitution of a human hematological and immune system in a severely immunodeficient mouse,” said Philippe Genne, CEO of Oncodesign. “Our mouse humanization platform means our customers can have these models in house or let us carry out their preclinical evaluation in our labs.” The procedures and characterization of the humanized models are presented in the two posters produced in conjunction with Oncodesign’s scientific partners (#394, #4169).

Oncodesign’s core business is the evaluation of new therapies in oncology. This is represented by four posters produced in conjunction with the company’s customers (#571, #1367, #5459, #5490). Oncodesign’s world-class in vitro and in vivo pharmacology platform has made significant contributions to the biodistribution and the efficacy of Oncodesign’s customers’ products. In the context of this translational research, Oncodesign’s scientific team will present its results with biomarkers of antitumoral efficacy using MRI and with serum biomarkers for the development of bone metastases in tumors of the prostate in the Nude rat.

The last innovation presented is the process of translational drug discovery which combines the Nanocyclix® medicinal chemistry technology and the in vivo pharmacological approach (#740). “Our goal is to offer our customers access to highly specific kinases and to discover new therapeutic molecules or imaging biomarkers using biological assays very close to clinical reality.”

The latest discoveries in medical and scientific oncology from the four corners of the world are shown every year at the AACR convention. Hundreds of presentations and talks on oncology are given by international experts leading the fight against cancer. Three members of Oncodesign’s scientific team will be present and able to comment on the results described in the following posters:
Poster titles
- Partnered R&D:
  - #394: Development of a fully human immune system in NOD/SCID/IL2Rgamma (NSG) mice for oncology research purposes
  - #4169: CReMEC initiative: Characterization of patient-derived colorectal tumor models and correlation with patient profile
  - #2255: In vivo study of serum cancer biomarkers and pain-induced bone metastasis of human prostate tumor in Nude rats

Customer research:
- #571: PK and antitumor activity of DEBIO 0507, a new platinum derivative, in preclinical tumor models
- #1367: The dual selective VEGFR-FGFR kinases inhibitor E-3810 decreases tumor perfusion and inhibits tumor growth: an analysis using dynamic contrast-enhanced magnetic resonance imaging
- #5459: Antitumor activity of EP80061, a small-glyco drug in preclinical studies
- #5490: In vitro and in vivo evaluation of LipoFufol, a new triple stealth liposomal formulation of modulated 5-FU: impact on efficacy and toxicity

Internal R&D:
- #740: Oncodesign translational drug discovery process

About Oncodesign Biotechnology SA
Oncodesign Biotechnology’s prime goal since its conception has been the identification of novel anticancer therapies. The company has developed an innovative preclinical research platform dedicated to establishing the in vitro and in vivo proof of concept of potential therapeutic agents. Its pharmacology based “Qualifying Approach”, aimed at the rapid evaluation of the therapeutic potential of novel molecules, and the translational perspective of Oncodesign create a continuum from drug target to patient.

In addition to its service offering, Oncodesign has significantly invested in its own technological R&D programs to increase its innovation base. Currently, Oncodesign has taken the lead in two important national initiatives, CReMEC (Medicen, Paris), which aims at the creation of a French resource centre for experimental oncology models based on primary tumor material, and PharmImage, a centre of excellence in pharmaco-imaging (Dijon, France). Starting from these research platforms, Oncodesign has continued to develop its business scope over the past year and is now offering capabilities and experience for the discovery of novel therapeutic and diagnostic agents through an integrated stand-alone approach.

Founded in 1995, by Dr Philippe Genne, Oncodesign Biotechnology is based in Dijon, France. It employs 60 people including 12 PhDs and has a worldwide client-base of over 400 large and small companies.

For more information on Oncodesign Biotechnology’s R&D platform and its services: www.oncodesign.com.

Contact for Media & Analysts:

Andrew Lloyd & Associates
Neil Hunter/Andrew Lloyd
neil@ala.com/allo@ala.com
Tel: +44 1273 675 100